[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hyundai Bioscience Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100639752","phase-2-a-study-of-cp-cov03-compared-with-placebo-in-participants-with-dengue-part-1-and-dengue-like-illness-part-2-100639752",false,"NCT07576868","A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) \u002F Dengue and Dengue-like Illness Patients (Part 2)","Inclusion Criteria:\n\n* Patients who are 18 years or over of age at time of screening.\n* Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.\n* Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)\n\nExclusion Criteria:\n\n* Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)\n* Patients who have previously received dengue vaccine\n* Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease","ALL","18 Years",{"count":19,"type":20},210,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This is a randomized, double-blind, placebo-controlled Phase 2\u002F3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.",[27],"Dengue",[29,30,31],"dengue","dengue treatment","dengue antiviral","RECRUITING","2026-07-08",{"date":35,"type":36},"2026-07-10","ACTUAL",{"date":38,"type":36},"2026-04-09",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Hyundai Bioscience Co., Ltd.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100646984","phase-1-safety-tolerability-and-efficacy-of-cp-pca07-in-combination-with-enzalutamide-in-patients-with-castration-resistant-prostate-cancer-100646984","NCT07683013","Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer","An Open-Label, Dose-Escalation, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n* 1\\. Male patients aged ≥19 years at the time of providing written informed consent.\n* 2\\. Patients with histologically or cytologically confirmed castration-resistant prostate cancer without small-cell features, who have experienced treatment failure with monotherapy of Enzalutamide or Abiraterone.\n* 3\\. Patients with a serum testosterone level \\\u003C 50 ng\u002FdL at screening.\n* 4\\. Patients with an increase in PSA compared to baseline, confirmed by two consecutive measurements within 8 weeks prior to the date of written informed consent (with at least 1 week between measurements and an increase of ≥ 50% compared to baseline).\n* 5\\. Patients with PSA levels ≥ 2 ng\u002FmL both prior to the date of written informed consent and at screening.\n* 6\\. Patients with an ECOG performance status ≤ 2 and an expected survival of at least 6 months.\n* 7\\. Patients whose spouse or partner is a woman of childbearing potential must agree to use one of the protocol-specified highly effective methods of contraception from the time of study participation consent until 3 months after the last administration of the investigational product.\n* 8\\. Patients who voluntarily agree to participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Patients who have received chemotherapy, chemoradiotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks prior to the first administration of the investigational product (for docetaxel or cabazitaxel therapy, within 9 weeks prior to the screening date).\n* 2\\. Patients diagnosed with immunodeficiency or who are in an immune-suppressed condition.\n* 3\\. Patients with autoimmune diseases.\n* 4\\. Patients with a pacemaker or severe heart failure \\[Class III or IV heart failure according to the New York Heart Association (NYHA) classification\\], or patients with uncontrolled arrhythmia (all patients with implanted medical devices other than a pacemaker are excluded).\n* 5\\. Patients with a history of chronic liver disease or evidence of cirrhosis.\n* 6\\. Patients with a history of gastrectomy or other conditions that may affect drug absorption.\n* 7\\. Patients with a history of deep vein thrombosis, pulmonary embolism, acute coronary syndrome, or major cerebrovascular disease within 6 months prior to screening.\n* 8\\. Patients with a history of major surgery requiring general anesthesia or assisted ventilation within 4 weeks prior to screening.\n* 9\\. Patients with active hepatitis B, a history of hepatitis B, or known active hepatitis C virus infection at screening.\n* 10\\. Patients who meet any of the following laboratory criteria at screening:\n* ① Absolute neutrophil count (ANC) \\\u003C 1,500\u002FuL without G-CSF administration within 2 weeks prior to screening\n* ② Platelet \\\u003C 100,000\u002FuL without transfusion within 2 weeks prior to screening\n* ③ Hemoglobin \\\u003C 9.0 g\u002FdL without transfusion within 2 weeks prior to screening\n* ④ Serum creatinine \\> 1.8 mg\u002FdL or eGFR (or GFR) \\\u003C 40 mL\u002Fmin\u002F1.73 m2\n* ⑤ AST and ALT \\> 2.5 x ULN\n* ⑥ Total bilirubin \\> 2.0 x ULN\n* 11\\. Patients expected to have hypersensitivity to the active ingredient or components of the investigational product.\n* 12\\. Patients who have received another investigational drug or investigational medical device within 4 weeks prior to the first administration of the investigational product.\n* 13\\. Patients deemed by the investigator to be unsuitable for participation in the study or unable to comply with the study requirements due to other diseases or conditions.","MALE","19 Years",{"count":54,"type":20},18,[56],"PHASE1","The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).\n\nThis is an open-label, dose-escalation, multicenter Phase 1 study. The primary objective is to assess the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) to determine the recommended Phase 2 dose (RP2D) of the combination therapy.\n\nThe secondary objective is to assess changes in Prostate-Specific Antigen (PSA) levels and pharmacokinetic characteristics.\n\nExploratory objectives include assessment of tumor response, disease control, progression-free survival, and biomarker analyses, including AR-V7 status, according to RECIST version 1.1 and other applicable criteria.",[59],"Castration-Resistant Prostate Cancer (CRPC)",[61,62,63,64,65,66,67],"Castration-resistant prostate cancer","CRPC","CP-PCA07","Enzalutamide","Niclosamide","Phase 1","Dose escalation","NOT_YET_RECRUITING","2026-07-02",{"date":71,"type":36},"2026-07-06",{"date":73,"type":20},"2026-07",{"date":75,"type":20},"2027-12",{"name":42,"class":43},1,""]